Biosimilars
35 results
Applied filters
The licence and supporting evidence for eculizumab biosimilars
11 September 2024Two licensed eculizumab biosimilars are available: Bekemv and Epysqli. Learn about the licensed indications, supporting evidence and key differences.
Preparing to use eculizumab biosimilar
12 March 2024Introducing biosimilar eculizumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.
The licence and supporting evidence for natalizumab biosimilar
14 February 2024One licensed natalizumab biosimilar is available: Tyruko. Learn about the licensed indications and supporting evidence.
National Homecare Medicines Committee (NHMC) Homecare Risk Assessment
10 December 2019To support organisations in establishing a robust risk assessment process for new homecare medicines services the NHMC has developed a tool for local use. …
National Homecare Medicines Committee (NHMC) Proposal for the funding of Pharmacy Homecare Teams
4 May 2018NHMC submitted a proposal for the funding of Trust Pharmacy Homecare Teams to NHS England and NHS Clinical Commissioning for consideration. The NHMC hopes that…
NHMC Good Practice Principles for the Provision of Manufacturer Funded Homecare Services
5 March 2018These Good Practice Principles set out the National Homecare Medicines Committee’s (NHMC) expectations of Manufacturers offering Manufacturer Funded Homecare Medicine Services in relation to the…
Preparing to use natalizumab biosimilar
6 February 2024Natalizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team.
Understanding patents
11 July 2025Patents allow the inventor a finite period of monopoly in exchange for publicising the idea. We explain how they work with respect to medicines.
The licence and supporting evidence for denosumab 60mg biosimilars
21 November 2025Denosumab 60mg biosimilars are licensed. Learn about indications, formulations, supporting evidence and differences.
The licence and supporting evidence for golimumab biosimilar
28 November 2025We highlight evidence for licensed golimumab biosimilar(s) and differences between the biosimilar(s) and the reference product (Simponi).